Pfizer Stock Price, News & Analysis (NYSE:PFE)

$35.54 0.19 (0.54 %)
(As of 11/21/2017 04:00 PM ET)
Previous Close$35.35
Today's Range$35.38 - $35.73
52-Week Range$30.51 - $36.78
Volume12.65 million shs
Average Volume20.20 million shs
Market Capitalization$211.84 billion
P/E Ratio14.15
Dividend Yield3.62%
Beta1.01

About Pfizer (NYSE:PFE)

Pfizer logoPfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines, as well as products for consumer healthcare. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology, rare diseases and consumer healthcare. EH includes legacy brands, branded generics, generic sterile injectable products, biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. Its brands include Prevnar 13, Xeljanz, Eliquis, Lipitor, Celebrex, Pristiq and Viagra.


Industry, Sector and Symbol:
  • Industry: Pharmaceuticals
  • Sub-Industry: Pharmaceuticals
  • Sector: Healthcare
  • Symbol: NYSE:PFE
  • CUSIP: 71708110
  • Web: www.pfizer.com
Debt:
  • Debt-to-Equity Ratio: 0.56%
  • Current Ratio: 1.43%
  • Quick Ratio: 1.15%
Price-To-Earnings:
  • Trailing P/E Ratio: 14.15
  • Forward P/E Ratio: 13.67
  • P/E Growth: 2.5
Sales & Book Value:
  • Annual Sales: $52.82 billion
  • Price / Sales: 4.01
  • Cash Flow: $3.40 per share
  • Price / Cash: 10.46
  • Book Value: $9.86 per share
  • Price / Book: 3.60
Dividend:
  • Annual Dividend: $1.28
  • Dividend Yield: 3.6%
Profitability:
  • Trailing EPS: $1.63
  • Net Income: $7.22 billion
  • Net Margins: 18.69%
  • Return on Equity: 25.41%
  • Return on Assets: 8.90%
Misc:
  • Employees: 96,500
  • Outstanding Shares: 5,960,710,000
 

Frequently Asked Questions for Pfizer (NYSE:PFE)

What is Pfizer's stock symbol?

Pfizer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PFE."

How often does Pfizer pay dividends? What is the dividend yield for Pfizer?

Pfizer declared a quarterly dividend on Wednesday, September 27th. Stockholders of record on Friday, November 10th will be given a dividend of $0.32 per share on Friday, December 1st. This represents a $1.28 dividend on an annualized basis and a dividend yield of 3.60%. The ex-dividend date is Thursday, November 9th. View Pfizer's Dividend History.

How were Pfizer's earnings last quarter?

Pfizer, Inc. (NYSE:PFE) released its earnings results on Tuesday, October, 31st. The biopharmaceutical company reported $0.67 EPS for the quarter, beating analysts' consensus estimates of $0.65 by $0.02. The biopharmaceutical company had revenue of $13.17 billion for the quarter, compared to the consensus estimate of $13.17 billion. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. The company's revenue for the quarter was up .9% compared to the same quarter last year. During the same quarter last year, the firm earned $0.61 EPS. View Pfizer's Earnings History.

When will Pfizer make its next earnings announcement?

Pfizer is scheduled to release their next quarterly earnings announcement on Monday, January, 29th 2018. View Earnings Estimates for Pfizer.

What guidance has Pfizer issued on next quarter's earnings?

Pfizer updated its FY17 earnings guidance on Tuesday, October, 31st. The company provided EPS guidance of $2.58-2.62 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.56. The company issued revenue guidance of $52.4-53.1 billion, compared to the consensus revenue estimate of $52.76 billion.

Where is Pfizer's stock going? Where will Pfizer's stock price be in 2017?

17 brokers have issued 1 year price targets for Pfizer's stock. Their predictions range from $31.00 to $53.00. On average, they anticipate Pfizer's stock price to reach $38.60 in the next twelve months. View Analyst Ratings for Pfizer.

What are Wall Street analysts saying about Pfizer stock?

Here are some recent quotes from research analysts about Pfizer stock:

  • 1. According to Zacks Investment Research, "Pfizer is facing headwinds in the form of genericization of key drugs, lost alliance revenues, pricing pressure and rising competition which is hurting the top-line. Though Pfizer’s growing immuno-oncology portfolio offers strong potential, many of these assets are in early stage of development. Additionally, Pfizer’s shares have underperformed the industry this year so far. Nonetheless, we believe that new products like Ibrance, contribution from acquisitions, cost-cutting efforts and share buybacks should help the company achieve its guidance. Pfizer also boasts a strong pipeline and expects approximately 25 to 30 drug approvals over the next five years, including around 15 products that have blockbuster potential. Bavencio is being considered a key long-term growth driver for Pfizer. The company has a mixed record of earnings surprises in recent quarters. Estimates have remained stable ahead of its Q3 earnings results." (10/11/2017)
  • 2. BMO Capital Markets analysts commented, "We are highly confident the deal will close as the purchase agreement removes IP risk and development risks, and creates significant shareholder value. We believe there is minimal risk for the deal being blocked due to anti-trust considerations CTP-543 Phase IIa initiated with top-line results expected 1Q18. The phase IIa trial will enroll approximately 100 patients spread across 4 active arms of differing doses (4, 8, 12 and 16 mg BID) and a placebo comparator. The primary endpoint for the trial will be measured using the severity of alopecia tool (SALT) after patients undergo 24 weeks of dosing. An additional 28 weeks of dosing of CTP-543 is planned for all patients enrolled in the study. If successfully developed, we anticipate a significant pricing discount for CTP-543 relative to Jakafi – owned by Incyte (INCY, Non-Rated). The earlier delay to initiate the trial due to clinical supply delays, which lasted around 2 months, has been resolved." (4/27/2017)
  • 3. UBS AG analysts commented, " The FDA approved Novartis' CDK4/6 agent, Kisqali (ribociclib), in first-line treatment for HR+/HER2- metastatic breast cancer in combo with any aromatase inhibitor. Recall that MONALEESA-2 was stopped early, and while interim data demonstrated a reduction in risk of disease progression or death by 44% over letrozole alone, the mPFS had not been reached at the time. For the first time, the label presented a mPFS of 25.3 mos for Kisqali + letrozole vs 16 mos for letrozole alone. The 9.3 mos improvement over letrozole is essentially comparable to 10.3 mos improvement (24.8 mos for Ibrance vs 14.5 mos for letrozole) for Pfizer's Ibrance. Given the strong interim data that were comparable to Ibrance, we believe the approval of Kisqali was largely expected. Our takeaway: Label looks a little worse than Ibrance. Overall, we think the label looks slightly worse, particularly on safety. On the positive, the label is broader, as the indication is for use of Kisqali in combo with anyaromatase inhibitors (vs Ibrance in combo with letrozole). However, as the vast majority of first-line use letrozole, the broader label shouldn't meaningfully impact Ibrance, in our view. We're not clear on how Kisqali got the broader label, but we think this could be encouraging for Ibrance, as the Ibrance label could also become as broad with the potential April approval of the confirmatory Phase 3 PALOMA-2 (Ibrance was approved under an accelerated pathway with Phase 2 PALOMA-1 data). On safety, the Kisqali label warns of QT prolongation and liver tox, which are not in the Ibrance label. We think the QT issue could put Kisqali at a disadvantage. Thoughts on the stock: Shouldn't impact the stock much, if anyIbrance has been on the market for ~2 years and has made significant headway to becoming a standard of therapy, and we do not believe there was anything in the Kisqali label that would meaningfully impact the significant lead that Pfizer has. In our CDK4/6 model, we assign a 5% share for Kisqali in 2017 that goes to 15%, 18%, and 20% in 2018-2020E." (3/14/2017)
  • 4. Jefferies Group LLC analysts commented, "We wanted to highlight a key data catalyst in which a positive outcome can drive shares higher: PIIa data for XEN801 for mod-to-severe acne in the latter part of Q1 (JEF est: ~Mar). We continue to like the risk/reward going into the data, especially on the heels of Dermira’s positive PIIb data for DRM01, which operates on the same pathway but more upstream. Reiterating Buy and $13 PT. Highlighting Key PIIa Data Catalyst in Latter Part of Q1: We wanted to take the opportunity to highlight a key data catalyst in which a positive outcome can drive shares higher: topline PIIa data catalyst for XEN801 for moderate-to-severe acne in the latter part of Q1 (JEF estimate: ~Mar). We previously conducted a review on XEN801 in April ’16, which can be found here, and now that the data catalyst is drawing near, we wanted to take the chance to highlight it again. To recap, the PIIa trial is a randomized, double- blind, multicentre, vehicle-controlled trial evaluating the efficacy and safety of patients with moderate-to-severe acne. The trial will compare XEN801 topical gel (1%) and matching placebo gel for 12 weeks with a 4-week follow-up. XENE has randomized 165 patients (v. 150 that was planned at conception), and has 85% power (v. 80% previously) to detect a ~16% difference." (1/19/2017)

Are investors shorting Pfizer?

Pfizer saw a decrease in short interest in October. As of October 31st, there was short interest totalling 51,408,403 shares, a decrease of 11.9% from the October 13th total of 58,325,639 shares. Based on an average trading volume of 17,276,742 shares, the days-to-cover ratio is presently 3.0 days. Currently, 0.9% of the shares of the company are sold short.

Who are some of Pfizer's key competitors?

Who are Pfizer's key executives?

Pfizer's management team includes the folowing people:

  • Ian C. Read, Chairman of the Board, Chief Executive Officer (Age 63)
  • Frank A. D'Amelio, Chief Financial Officer, Executive Vice President - Business Operations (Age 59)
  • Albert Bourla, Chief Operating Officer (Age 56)
  • Mikael Dolsten M.D., Ph.D., President - Worldwide Research and Development (Age 58)
  • John D. Young, Group President - Pfizer Innovative Health and Angela Hwang (Age 53)
  • Rady A. Johnson II, Executive Vice President, Chief Compliance and Risk Officer (Age 55)
  • Douglas M. Lankler, Executive Vice President, General Counsel (Age 51)
  • Charles H. Hill III, Executive Vice President - Worldwide Human Resources (Age 61)
  • Freda C. Lewis-Hall M.D., Executive Vice President, Chief Medical Officer (Age 62)
  • Kirsten Lund-Jurgensen, Executive Vice President, President - Pfizer Global Supply (Age 57)

Who owns Pfizer stock?

Pfizer's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Bank of New York Mellon Corp (1.06%), Ameriprise Financial Inc. (1.01%), Dimensional Fund Advisors LP (0.72%), Fisher Asset Management LLC (0.59%), Schwab Charles Investment Management Inc. (0.57%) and Capital International Investors (0.54%). Company insiders that own Pfizer stock include Albert Bourla, Alexander R Mackenzie, Anthony J Maddaluna, Charles H Hill, Douglas M Lankler, Frank A Damelio, Ian C Read, John D Young, Laurie J Olson, Loretta V Cangialosi, Mikael Dolsten, Rady A Johnson and Sally Susman. View Institutional Ownership Trends for Pfizer.

Who sold Pfizer stock? Who is selling Pfizer stock?

Pfizer's stock was sold by a variety of institutional investors in the last quarter, including Capital International Investors, Macquarie Group Ltd., APG Asset Management N.V., Janus Henderson Group PLC, Schroder Investment Management Group, Brandes Investment Partners LP, Dimensional Fund Advisors LP and Bank of New York Mellon Corp. Company insiders that have sold Pfizer company stock in the last year include Alexander R Mackenzie, Charles H Hill, Frank A Damelio, Ian C Read, Laurie J Olson, Mikael Dolsten, Rady A Johnson and Sally Susman. View Insider Buying and Selling for Pfizer.

Who bought Pfizer stock? Who is buying Pfizer stock?

Pfizer's stock was purchased by a variety of institutional investors in the last quarter, including Stifel Financial Corp, Longview Partners Guernsey LTD, Boston Partners, Epoch Investment Partners Inc., Prudential Financial Inc., TD Asset Management Inc., Ameriprise Financial Inc. and Assenagon Asset Management S.A.. View Insider Buying and Selling for Pfizer.

How do I buy Pfizer stock?

Shares of Pfizer can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pfizer's stock price today?

One share of Pfizer stock can currently be purchased for approximately $35.54.

How big of a company is Pfizer?

Pfizer has a market capitalization of $211.84 billion and generates $52.82 billion in revenue each year. The biopharmaceutical company earns $7.22 billion in net income (profit) each year or $1.63 on an earnings per share basis. Pfizer employs 96,500 workers across the globe.

How can I contact Pfizer?

Pfizer's mailing address is 235 E 42ND ST, NEW YORK, NY 10017-5703, United States. The biopharmaceutical company can be reached via phone at +1-212-5732323.


MarketBeat Community Rating for Pfizer (NYSE PFE)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  876 (Vote Outperform)
Underperform Votes:  452 (Vote Underperform)
Total Votes:  1,328
MarketBeat's community ratings are surveys of what our community members think about Pfizer and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Pfizer (NYSE:PFE)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 6 Hold Ratings, 10 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.53)
Consensus Price Target: $38.60 (8.61% upside)

Consensus Price Target History for Pfizer (NYSE:PFE)

Price Target History for Pfizer (NYSE:PFE)

Analysts' Ratings History for Pfizer (NYSE:PFE)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/16/2017Jefferies Group LLCSet Price TargetNeutral$39.00N/AView Rating Details
11/10/2017BMO Capital MarketsReiterated RatingBuy$39.00N/AView Rating Details
11/1/2017J P Morgan Chase & CoSet Price TargetBuy$39.00N/AView Rating Details
11/1/2017Goldman Sachs Group, Inc. (The)Set Price TargetNeutral$36.00N/AView Rating Details
10/31/2017Berenberg BankSet Price TargetNeutral$36.00N/AView Rating Details
10/11/2017Deutsche Bank AGSet Price TargetBuy$38.00N/AView Rating Details
10/11/2017Barclays PLCSet Price TargetBuy$38.00N/AView Rating Details
9/20/2017Morgan StanleyUpgradeEqual Weight -> Overweight$35.00 -> $39.00LowView Rating Details
9/19/2017Sanford C. BernsteinSet Price TargetBuy$39.00LowView Rating Details
8/14/2017Cowen and CompanySet Price TargetBuy$43.00LowView Rating Details
7/20/2017Credit Suisse GroupDowngradeOutperform -> Neutral$38.00 -> $36.00LowView Rating Details
5/16/2017Citigroup Inc.DowngradeNeutral -> Sell$38.00 -> $31.00LowView Rating Details
3/23/2017Societe GeneraleReiterated RatingNeutral$36.00LowView Rating Details
2/2/2017Morningstar, Inc.Reiterated RatingBuyN/AView Rating Details
2/1/2017Atlantic SecuritiesSet Price TargetBuy$37.00N/AView Rating Details
1/21/2017Piper Jaffray CompaniesSet Price TargetBuy$53.00N/AView Rating Details
12/2/2016GuggenheimInitiated CoverageNeutralN/AView Rating Details
11/7/2016Bank of America CorporationReiterated RatingBuy$40.00 -> $36.00N/AView Rating Details
11/2/2016ArgusDowngradeBuy -> HoldN/AView Rating Details
5/4/2016Independent Research GmbHSet Price TargetNeutral$37.00N/AView Rating Details
5/2/2016Leerink SwannLower Price TargetMarket Perform$37.00 -> $34.70N/AView Rating Details
4/12/2016S&P Equity ResearchReiterated RatingBuyN/AView Rating Details
2/16/2016SunTrust Banks, Inc.Lower Price TargetNeutral$37.00 -> $33.00N/AView Rating Details
1/26/2016Nord/LBReiterated RatingBuyN/AView Rating Details
11/24/2015Evercore ISIReiterated RatingBuy$38.00N/AView Rating Details
(Data available from 11/21/2015 forward)

Earnings

Earnings History and Estimates Chart for Pfizer (NYSE:PFE)

Earnings by Quarter for Pfizer (NYSE:PFE)

Earnings History by Quarter for Pfizer (NYSE PFE)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
1/29/2018N/AView Earnings Details
10/31/2017Q3 2017$0.65$0.67$13.17 billion$13.17 billionViewN/AView Earnings Details
8/1/2017Q2 2017$0.65$0.67$13.08 billion$12.90 billionViewListenView Earnings Details
5/2/2017Q1 2017$0.67$0.69$13.09 billion$12.78 billionViewListenView Earnings Details
1/31/2017Q416$0.50$0.47$13.64 billion$13.60 billionViewN/AView Earnings Details
11/1/2016Q3$0.62$0.61$13.05 billion$13.05 billionViewN/AView Earnings Details
8/2/2016Q216$0.62$0.64$13.01 billion$13.10 billionViewN/AView Earnings Details
5/3/2016Q116$0.55$0.67$12.00 billion$13.00 billionViewN/AView Earnings Details
2/2/2016Q415$0.52$0.53$13.57 billion$14.05 billionViewN/AView Earnings Details
10/27/2015Q315$0.51$0.60$11.56 billion$12.10 billionViewListenView Earnings Details
7/28/2015Q215$0.52$0.56$11.39 billion$11.00 billionViewListenView Earnings Details
4/28/2015Q115$0.49$0.51$10.79 billion$10.86 billionViewN/AView Earnings Details
1/27/2015Q414$0.53$0.54$12.94 billion$13.10 billionViewN/AView Earnings Details
10/28/2014Q314$0.55$0.57$12.24 billion$12.40 billionViewN/AView Earnings Details
7/29/2014Q214$0.57$0.58$12.49 billion$12.80 billionViewN/AView Earnings Details
5/5/2014Q114$0.56$0.57$12.07 billion$11.35 millionViewN/AView Earnings Details
1/27/2014Q413$0.52$0.56$13.35 billion$13.56 billionViewN/AView Earnings Details
10/29/2013Q313$0.56$0.58$12.69 billion$12.64 billionViewN/AView Earnings Details
7/30/2013Q2 2013$0.55$0.56$13.02 billion$12.97 billionViewListenView Earnings Details
4/30/2013Q1 2013$0.55$0.54$14.10 billion$13.50 billionViewListenView Earnings Details
1/29/2013Q4 2012$0.44$0.47$14.40 billion$15.10 billionViewListenView Earnings Details
11/1/2012Q312$0.53$0.53$14.64 billion$14.00 billionViewN/AView Earnings Details
7/31/2012$0.54$0.62ViewN/AView Earnings Details
5/1/2012$0.57$0.58ViewN/AView Earnings Details
1/31/2012$0.47$0.50ViewN/AView Earnings Details
11/1/2011$0.55$0.62ViewN/AView Earnings Details
8/2/2011$0.59$0.60ViewN/AView Earnings Details
5/3/2011$0.59$0.60ViewN/AView Earnings Details
2/1/2011$0.46$0.47ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Pfizer (NYSE:PFE)
2017 EPS Consensus Estimate: $2.51
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$0.67$0.67$0.67
Q2 20173$0.62$0.65$0.64
Q3 20173$0.64$0.65$0.64
Q4 20172$0.55$0.56$0.56
(Data provided by Zacks Investment Research)

Dividends

Current Dividend Information for Pfizer (NYSE:PFE)

Next Dividend:12/1/2017
Annual Dividend:$1.28
Dividend Yield:3.60%
Dividend Growth:7.70% (3 Year Average)
Payout Ratio:78.53% (Trailing 12 Months of Earnings)
49.23% (Based on This Year's Estimates)
46.72% (Based on Next Year's Estimates)
Track Record:7 Years of Consecutive Dividend Growth
Frequency:Quarterly Dividend
Dividend Payments by Quarter for Pfizer (NYSE:PFE)

Dividend History by Quarter for Pfizer (NYSE PFE)

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
9/27/2017quarterly$0.323.6%11/9/201711/10/201712/1/2017
6/22/2017quarterly$0.323.75%8/2/20178/4/20179/1/2017
4/28/2017quarterly$0.323.77%5/10/20175/12/20176/1/2017
12/12/2016quarterly$0.323.9%2/1/20172/3/20173/1/2017
9/23/2016quarterly$0.303.5%11/8/201611/11/201612/1/2016
6/23/2016quarterly$0.303.53%8/3/20168/5/20169/1/2016
4/28/2016quarterly$0.303.67%5/11/20165/13/20166/1/2016
12/14/2015quarterly$0.303.72%2/3/20162/5/20163/2/2016
9/25/2015quarterly$0.283.63%11/4/201511/6/201512/1/2015
6/25/2015quarterly$0.283.3%8/5/20158/7/20159/2/2015
4/23/2015quarterly$0.283.18%5/6/20155/8/20156/2/2015
12/15/2014quarterly$0.283.65%2/4/20152/6/20153/3/2015
10/23/2014quarterly$0.263.57%11/5/201411/7/201412/2/2014
6/26/2014quarterly$0.263.51%7/30/20148/1/20149/3/2014
4/25/2014quarterly$0.263.38%5/7/20145/9/20146/3/2014
12/16/2013quarterly$0.263.45%2/5/20142/7/20143/4/2014
10/24/2013quarterly$0.243.14%11/6/201311/8/201312/3/2013
6/27/2013quarterly$0.243.43%7/31/20138/2/20139/4/2013
4/25/2013quarterly$0.243.19%5/8/20135/10/20136/4/2013
12/17/2012quarterly$0.243.74%1/30/20132/1/20133/5/2013
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Pfizer (NYSE PFE)

Insider Ownership Percentage: 0.06%
Institutional Ownership Percentage: 69.34%
Insider Trades by Quarter for Pfizer (NYSE:PFE)
Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Insider Trades by Quarter for Pfizer (NYSE PFE)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/1/2017Alexander R MackenzieInsiderSell14,700$35.30$518,910.00View SEC Filing  
10/2/2017Alexander R MackenzieEVPSell7,350$35.65$262,027.50View SEC Filing  
9/12/2017Sally SusmanInsiderSell38,230$35.00$1,338,050.00View SEC Filing  
9/1/2017Alexander R MackenzieInsiderSell7,350$34.00$249,900.00View SEC Filing  
8/31/2017Alexander R MackenzieInsiderSell7,350$34.00$249,900.00View SEC Filing  
8/31/2017Frank A DamelioEVPSell94,409$34.00$3,209,906.00View SEC Filing  
8/31/2017Ian C ReadCEOSell197,168$34.00$6,703,712.00View SEC Filing  
8/21/2017Laurie J OlsonInsiderSell8,064$32.70$263,692.80View SEC Filing  
8/7/2017Alexander R MackenzieInsiderSell15,000$33.50$502,500.00View SEC Filing  
8/4/2017Ian C. ReadCEOSell96,950$34.00$3,296,300.00View SEC Filing  
3/10/2017Rady A JohnsonInsiderSell4,500$34.19$153,855.00View SEC Filing  
3/9/2017Charles H HillInsiderSell36,000$34.07$1,226,520.00View SEC Filing  
3/2/2017Mikael DolstenInsiderSell30,970$34.51$1,068,774.70View SEC Filing  
11/9/2016Anthony J MaddalunaInsiderSell10,000$33.00$330,000.00View SEC Filing  
11/4/2016Albert BourlaInsiderSell18,390$30.05$552,619.50View SEC Filing  
5/26/2016Frank A DamelioEVPSell100,000$34.49$3,449,000.00View SEC Filing  
5/24/2016Loretta V CangialosiVPSell86,000$33.97$2,921,420.00View SEC Filing  
5/11/2016Laurie J OlsonEVPSell4,700$33.50$157,450.00View SEC Filing  
5/10/2016Frank A DamelioEVPSell192,000$33.66$6,462,720.00View SEC Filing  
5/10/2016John D YoungInsiderSell41,700$33.53$1,398,201.00View SEC Filing  
5/9/2016Anthony J MaddalunaEVPSell8,950$33.75$302,062.50View SEC Filing  
5/9/2016Ian C ReadCEOSell275,000$33.80$9,295,000.00View SEC Filing  
5/5/2016Sally SusmanEVPSell76,116$33.75$2,568,915.00View SEC Filing  
5/4/2016Douglas M LanklerEVPSell29,700$33.69$1,000,593.00View SEC Filing  
5/4/2016Mikael DolstenInsiderSell67,588$33.46$2,261,494.48View SEC Filing  
5/3/2016Frank A DamelioEVPSell87,079$33.65$2,930,208.35View SEC Filing  
10/6/2015Pfizer Incmajor shareholderBuy714,285$7.00$4,999,995.00View SEC Filing  
6/11/2015Laurie J OlsonEVPSell26,000$34.39$894,140.00View SEC Filing  
3/12/2015Sally SusmanEVPSell46,179$34.00$1,570,086.00View SEC Filing  
2/13/2015Loretta V CangialosiVPSell104,000$34.73$3,611,920.00View SEC Filing  
2/12/2015Anthony J MaddalunaEVPSell9,000$34.85$313,650.00View SEC Filing  
2/11/2015Frank A DamelioEVPSell14,800$34.30$507,640.00View SEC Filing  
2/10/2015Anthony J MaddalunaEVPSell9,000$33.78$304,020.00View SEC Filing  
12/8/2014Anthony J MaddalunaEVPSell6,500$32.00$208,000.00View SEC Filing  
11/10/2014Charles H HillEVPSell8,285$30.18$250,041.30View SEC Filing  
11/7/2014John D YoungInsiderSell21,600$29.89$645,624.00View SEC Filing  
10/29/2014Anthony J MaddalunaEVPSell2,425$29.56$71,683.00View SEC Filing  
6/12/2014Laurie J OlsonEVPSell36,275$29.53$1,071,200.75View SEC Filing  
6/2/2014Geno J GermanoInsiderSell30,000$29.68$890,400.00View SEC Filing  
3/17/2014John YoungInsiderSell9,000$31.38$282,420.00View SEC Filing  
3/4/2014Loretta CangialosiVPSell102,943$32.05$3,299,323.15View SEC Filing  
3/4/2014Mikael DolstenInsiderSell35,789$32.58$1,166,005.62View SEC Filing  
3/4/2014Sally SusmanEVPSell67,585$32.59$2,202,595.15View SEC Filing  
1/13/2014Frank DamelioEVPSell131,810$30.82$4,062,384.20View SEC Filing  
11/1/2013Anthony J MaddalunaEVPSell43,500$31.02$1,349,370.00View SEC Filing  
11/1/2013Loretta V CangialosiVPSell10,000$31.20$312,000.00View SEC Filing  
10/28/2013Ian C ReadCEOSell338,000$30.57$10,332,660.00View SEC Filing  
9/16/2013Freda Lewis-HallEVPSell38,461$28.70$1,103,830.70View SEC Filing  
7/31/2013Charles H HillEVPSell96,500$29.64$2,860,260.00View SEC Filing  
7/31/2013Loretta V CangialosiVPSell14,688$29.63$435,205.44View SEC Filing  
5/15/2013Amy W SchulmanEVPSell70,000$29.36$2,055,200.00View SEC Filing  
5/15/2013Ian C ReadCEOSell69,900$29.39$2,054,361.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Pfizer (NYSE PFE)

Source:
DateHeadline
Interesting December Stock Options for PFEInteresting December Stock Options for PFE
www.nasdaq.com - November 21 at 9:16 AM
ETFs with exposure to Pfizer Inc. : November 20, 2017ETFs with exposure to Pfizer Inc. : November 20, 2017
finance.yahoo.com - November 21 at 9:16 AM
Britain says Canadas Concordia overcharging health service for thyroid drugBritain says Canada's Concordia overcharging health service for thyroid drug
finance.yahoo.com - November 21 at 9:16 AM
Drug firm Concordia overcharged Britains health service with 6,000 pct price riseDrug firm Concordia overcharged Britain's health service with 6,000 pct price rise
finance.yahoo.com - November 21 at 9:16 AM
November Pharma And Biotech Dividend Stocks To Look Out ForNovember Pharma And Biotech Dividend Stocks To Look Out For
finance.yahoo.com - November 21 at 9:16 AM
Pfizer, Inc. (PFE) Given Average Recommendation of "Hold" by AnalystsPfizer, Inc. (PFE) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - November 21 at 6:24 AM
NCCN, in Collaboration with Pfizer, Awards Nine Grants for Quality Improvement in Breast Cancer CareNCCN, in Collaboration with Pfizer, Awards Nine Grants for Quality Improvement in Breast Cancer Care
www.prnewswire.com - November 20 at 2:36 PM
Pfizer (PFE) a Hold on Pallid Sales Growth - Investorplace.comPfizer (PFE) a Hold on Pallid Sales Growth - Investorplace.com
investorplace.com - November 18 at 10:52 AM
Why Its Time to Put Pfizer Inc. Stock on Your Watchlist - Investorplace.comWhy It's Time to Put Pfizer Inc. Stock on Your Watchlist - Investorplace.com
investorplace.com - November 18 at 10:52 AM
Nevada refusing Pfizer demand for return of execution drugsNevada refusing Pfizer demand for return of execution drugs
finance.yahoo.com - November 18 at 10:52 AM
The Latest: Nevada wont return execution drug to PfizerThe Latest: Nevada won't return execution drug to Pfizer
marketbeat.com - November 18 at 1:07 AM
Nevada wants to use untried execution drugs that pose risksNevada wants to use untried execution drugs that pose risks
marketbeat.com - November 17 at 8:26 PM
Pfizer tells Nebraska not to use its drugs in executionPfizer tells Nebraska not to use its drugs in execution
marketbeat.com - November 17 at 2:49 PM
Pfizer (PFE) a Hold on Pallid Sales GrowthPfizer (PFE) a Hold on Pallid Sales Growth
investorplace.com - November 17 at 12:21 PM
Pfizer, Inc. (PFE) Given a $39.00 Price Target by Jefferies Group LLC AnalystsPfizer, Inc. (PFE) Given a $39.00 Price Target by Jefferies Group LLC Analysts
www.americanbankingnews.com - November 16 at 8:24 PM
Zacks: Analysts Anticipate Pfizer, Inc. (PFE) Will Announce Earnings of $0.56 Per ShareZacks: Analysts Anticipate Pfizer, Inc. (PFE) Will Announce Earnings of $0.56 Per Share
www.americanbankingnews.com - November 16 at 11:38 AM
Pfizer, Inc. (PFE) Sees Large Decrease in Short InterestPfizer, Inc. (PFE) Sees Large Decrease in Short Interest
www.americanbankingnews.com - November 15 at 1:58 AM
How to Know if You Should Buy, Sell or Hold Pfizer Inc.How to Know if You Should Buy, Sell or Hold Pfizer Inc.
investorplace.com - November 14 at 2:30 PM
Analyst: Is The Street Ignoring Pfizer And Its Upcoming Catalysts? - BenzingaAnalyst: Is The Street Ignoring Pfizer And Its Upcoming Catalysts? - Benzinga
www.benzinga.com - November 14 at 6:45 AM
Pfizer (PFE) Names Albert Bourla as COO - StreetInsider.com - StreetInsider.comPfizer (PFE) Names Albert Bourla as COO - StreetInsider.com - StreetInsider.com
www.streetinsider.com - November 14 at 6:45 AM
Interesting January 2020 Stock Options for PFE - NasdaqInteresting January 2020 Stock Options for PFE - Nasdaq
www.nasdaq.com - November 14 at 6:45 AM
This Simple, Lifesaving Liquid Is Suddenly in Short SupplyThis Simple, Lifesaving Liquid Is Suddenly in Short Supply
finance.yahoo.com - November 14 at 6:45 AM
Pfizer Sells Stake in Chinas Hisun, Ending Drugs Joint VenturePfizer Sells Stake in China's Hisun, Ending Drugs Joint Venture
finance.yahoo.com - November 12 at 11:33 AM
Pfizer exits China joint venture for generic drugsPfizer exits China joint venture for generic drugs
finance.yahoo.com - November 12 at 11:33 AM
Pfizers (PFE) "Buy" Rating Reiterated at BMO Capital MarketsPfizer's (PFE) "Buy" Rating Reiterated at BMO Capital Markets
www.americanbankingnews.com - November 12 at 6:28 AM
Pfizer (PFE) Quant Score Hurt RatingPfizer (PFE) Quant Score Hurt Rating
investorplace.com - November 10 at 8:06 AM
Pfizer, Inc. (PFE) Ex-Dividend Date Scheduled for November 09, 2017 - NasdaqPfizer, Inc. (PFE) Ex-Dividend Date Scheduled for November 09, 2017 - Nasdaq
www.nasdaq.com - November 9 at 11:31 AM
Behind Pfizer’s Corporate and Pipeline Developments in 3Q17Behind Pfizer’s Corporate and Pipeline Developments in 3Q17
finance.yahoo.com - November 9 at 11:31 AM
Understanding Pfizer’s Valuation after the 3Q17 ResultsUnderstanding Pfizer’s Valuation after the 3Q17 Results
finance.yahoo.com - November 9 at 11:31 AM
Here's What Cost GlaxoSmithKline PLC Nearly $10 Billion in Market Cap in OctoberHere's What Cost GlaxoSmithKline PLC Nearly $10 Billion in Market Cap in October
finance.yahoo.com - November 9 at 11:31 AM
ETFs with exposure to Pfizer Inc. : November 8, 2017ETFs with exposure to Pfizer Inc. : November 8, 2017
finance.yahoo.com - November 9 at 11:31 AM
Arkansas got execution drug made by resistant manufacturerArkansas got execution drug made by resistant manufacturer
finance.yahoo.com - November 9 at 11:31 AM
AstraZeneca earnings fall amid patent protection lossesAstraZeneca earnings fall amid patent protection losses
marketbeat.com - November 9 at 4:10 AM
Spark Therapeutics (ONCE), Pfizer (PFE) Amend Pact for Investigational SPK-9001 in Hemophilia B - StreetInsider.comSpark Therapeutics (ONCE), Pfizer (PFE) Amend Pact for Investigational SPK-9001 in Hemophilia B - StreetInsider.com
www.streetinsider.com - November 7 at 8:41 AM
These Key Products Contributed to Pfizer’s Growth in 3Q17These Key Products Contributed to Pfizer’s Growth in 3Q17
finance.yahoo.com - November 7 at 8:41 AM
Pharma Stock Roundup: Pfizer, Teva, Novartis, And MorePharma Stock Roundup: Pfizer, Teva, Novartis, And More
feeds.benzinga.com - November 6 at 12:54 PM
Pfizer, Inc. to Post FY2017 Earnings of $2.60 Per Share, SunTrust Banks Forecasts (PFE)Pfizer, Inc. to Post FY2017 Earnings of $2.60 Per Share, SunTrust Banks Forecasts (PFE)
www.americanbankingnews.com - November 6 at 3:26 AM
5 Things Pfizer's Management Just Said That You Don't Want to Miss5 Things Pfizer's Management Just Said That You Don't Want to Miss
finance.yahoo.com - November 4 at 4:34 PM
Pfizer (PFE) Sales Growth Hurts Rating - Investorplace.comPfizer (PFE) Sales Growth Hurts Rating - Investorplace.com
investorplace.com - November 4 at 8:49 AM
Pfizer (PFE) Sales Growth Hurts RatingPfizer (PFE) Sales Growth Hurts Rating
investorplace.com - November 3 at 8:04 AM
Why tax plan might not put US firms overseas cash to workWhy tax plan might not put US firms' overseas cash to work
marketbeat.com - November 3 at 4:36 AM
Pfizer, Inc. (PFE) EVP Alexander R. Mackenzie Sells 7,350 SharesPfizer, Inc. (PFE) EVP Alexander R. Mackenzie Sells 7,350 Shares
www.americanbankingnews.com - November 2 at 8:54 PM
Insider Selling: Pfizer, Inc. (PFE) Insider Sells 14,700 Shares of StockInsider Selling: Pfizer, Inc. (PFE) Insider Sells 14,700 Shares of Stock
www.americanbankingnews.com - November 2 at 8:54 PM
5 Things Pfizers Management Just Said That You Dont Want to Miss5 Things Pfizer's Management Just Said That You Don't Want to Miss
www.fool.com - November 2 at 10:35 AM
UroGen Pharma Appoints Former Kite Pharma Chief Operating Officer Cynthia M. Butitta to its Board of DirectorsUroGen Pharma Appoints Former Kite Pharma Chief Operating Officer Cynthia M. Butitta to its Board of Directors
feeds.benzinga.com - November 2 at 9:21 AM
FY2017 EPS Estimates for Pfizer, Inc. Boosted by Leerink Swann (PFE)FY2017 EPS Estimates for Pfizer, Inc. Boosted by Leerink Swann (PFE)
www.americanbankingnews.com - November 2 at 8:17 AM
Pfizer (PFE) Q3 2017 Results - Earnings Call TranscriptPfizer (PFE) Q3 2017 Results - Earnings Call Transcript
seekingalpha.com - November 2 at 7:41 AM
Former Pfizer property among the top real estate deals of OctoberFormer Pfizer property among the top real estate deals of October
www.bizjournals.com - November 2 at 7:41 AM
Pfizer Inc. – Value Analysis (NYSE:PFE) : November 1, 2017Pfizer Inc. – Value Analysis (NYSE:PFE) : November 1, 2017
finance.yahoo.com - November 2 at 7:40 AM
Prevnar Helps Pfizer Post Better Than Expected Q3 ResultsPrevnar Helps Pfizer Post Better Than Expected Q3 Results
finance.yahoo.com - November 2 at 7:40 AM

Social Media

Financials

Chart

Pfizer (NYSE PFE) Chart for Tuesday, November, 21, 2017
Loading chart…

This page was last updated on 11/21/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.